Video

Urology Times 50 Innovations Series: Urinary molecular biomarkers in prostate cancer

Author(s):

Urology Times staff

“Our ability to develop innovative technologies and approaches continues to evolve. We have newer molecular profiling techniques that are being applied to urine at the moment,” says Simpa Salami, MD, MPH.

Urology Times® is celebrating its 50th anniversary in 2022. To mark the occasion, we are highlighting 50 of the top innovations and developments that have transformed the field of urology over the past 50 years. In this installment, Simpa Salami, MD, MPH, discusses the development of urinary biomarkers in prostate cancer detection. Salami is an assistant professor of urology at the University of Michigan, Ann Arbor.

Related Videos
Daniel Kwon, MD, answers a question during a Zoom video interview
DNA helix | Image Credit: © BillionPhotos.com - stock.adobe.com
DNA molecules | Image Credit: © vitstudio - stock.adobe.com
Daniel Kwon, MD, answers a question during a Zoom video interview
Related Content
Study shows value of precision-based approaches in prostate cancer
May 19th 2025

Study shows value of precision-based approaches in prostate cancer

Hannah Clarke
The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.
Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer
February 25th 2025

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

Hannah Clarke
Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.
Pathogenic variants of WNT9B gene linked to hereditary prostate cancer
January 29th 2025

Pathogenic variants of WNT9B gene linked to hereditary prostate cancer

Hannah Clarke
WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.
Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear
January 22nd 2025

Genomic tests may offer valuable prognostic insights, but clinical utility remains unclear

Hannah Clarke
"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.
3d rendered genetic illustration of human dna under microscope created with generative ai technology | Image Credit: © Picture Studio - stock.adobe.com
December 24th 2024

Quiz: CUA guidelines on specimen and timing considerations with genetic testing

Patrick Campbell
Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.
NCCN reaffirms Prolaris’ prognostic value in prostate cancer
December 18th 2024

NCCN reaffirms Prolaris’ prognostic value in prostate cancer

Hannah Clarke
The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.
© 2025 MJH Life Sciences

All rights reserved.